International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the journal International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been performed in collaboration with the Karolinska Institute in Huddinge, Sweden and Truly labs in Lund, Sweden. The study confirms that proteins are released from NanoZolid® depots with maintained bio-functionality, illustrated by protein targeting to tumor cell receptors. The investigation was performed with fluorescence-imaging.
The NanoZolid® technology has during the last years been shown to enable a controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically validated effects over a desired time period. In this study, a fluorescence-labelled model substance, Epidermal Growth Factor (EGF) protein, was used and followed longitudinally in mice after subcutaneous injections of the NanoZolid depot implants. The labelled EGF accumulated in tumors that express receptors for EGF in the hind leg. The molecule size of EGF protein is 6 kDa which is similar with other polypeptides and smaller proteins relevant for anti-cancer treatment.
“We are delighted that the study results will be published in this prestigious journal marking an important cornerstone in showing the ability of NanoZolid® technology to address the challenges with systemic or local longer-term treatments of larger biomolecules. It also opens up new partnering possibilities as the acceptance of the study is an independent validation of our technology,” said Monica Wallter, CEO of LIDDS.
NanoZolid® depot formulated biological drugs for slow release offer the possibility to overcome issues with systemic or local frequent treatments and compliance. There is a large need for this type of technology in a diverse range of disease areas, including cancer, psychiatric, endocrine and autoimmune diseases. NanoZolid® depot for local release, e.g. intratumoral delivery of drugs, offers less injections, a decreased risk for systemic adverse effects and an increased quality of life.
The publication has the title “Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse” and will be found at:
when published, which is expected in a few weeks.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: email@example.com
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: firstname.lastname@example.org) For more information, please visit www.liddspharma.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 202110.4.2021 14:30:00 CEST | Press release
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a partial response in one pembrolizumab-resistant melanoma patient, and stable disease in multiple patients EOS-448 reduced TIGIT+ suppressive T regulatory cells and CD8 T cells considered to be exhausted at all tested doses, indicating engagement of FcγR, an essential component in many immune system effector functions Company to advance EOS-448 into combination trials with pembrolizumab and other novel agents in both checkpoint-naïve and resistant patients Company to host conference call on Monday, April 12th at 8:00 a.m. EDT to discuss results CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company
Notice to Annual General Meeting 20219.4.2021 21:45:00 CEST | Press release
Shareholders in MICRO SYSTEMATION AB (publ) are hereby given notice to attend the Annual General Meeting (AGM) on Tuesday, 11 May 2021, at 18.00 at MSAB’s premises at Hornsbruksgatan 28 in Stockholm. Registration for the AGM will commence at 17:15. Because of COVID-19 (the Corona virus), MSAB is prioritising health and safety and has thus decided to hold the AGM on Company premises, Hornsbruksgatan 28 in Stockholm, and keep the meeting as brief as possible and to provide the opportunity for shareholders to also vote by post. No food will be served. The demonstration and display of the Company’s products normally given in conjunction with the AGM are cancelled. Questions for Company management can be sent to email@example.com. Against the backdrop of recommendations issued by Swedish authorities, all shareholders are encouraged to consider utilising the possibility of voting by mail via a form which will be available on the Company’s website (www.msab.com/investors) rather than physically a
Kallelse till årsstämma 20219.4.2021 21:45:00 CEST | Pressemelding
Aktieägare i MICRO SYSTEMATION AB (publ) kallas härmed till årsstämma tisdagen den 11 maj 2021 kl. 18.00 i MSABs lokaler på Hornsbruksgatan 28 i Stockholm. Inregistrering till årsstämman börjar klockan 17:15. Med anledning av COVID-19 (Corona-viruset) har MSAB, för att sätta hälsa och säkerhet i första rummet, beslutat att hålla stämman i bolagets lokaler, Hornsbruksgatan 28 i Stockholm och att korta stämman så långt som möjligt, samt ge aktieägarna möjlighet att före stämman utöva sin rösträtt per post. Någon servering kommer inte att förekomma. Demonstration och visning av bolagets produkter som normalt görs i samband med stämman är inställd. Frågor till bolagsledningen kan skickas till firstname.lastname@example.org . Mot bakgrund av myndigheternas föreskrifter uppmanas alla aktieägare att överväga att istället för att närvara fysiskt vid stämman utnyttja möjligheten att poströsta via formulär på bolagets hemsida www.msab.com/investors. RÄTT TILL DELTAGANDE Aktieägare i Micro Systemation AB (publ),
RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag9.4.2021 18:43:18 CEST | Press release
Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 09 April 2021, purchased 9 shares of RomReal at NOK 1.75 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,475,739 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
CONDITIONS FOR PURCHASES OF CORPORATE BONDS9.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-14BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VATTENFALL AB: XS0328561286, 2022-11-01 STANGASTADEN AB: SE0012193860, 2024-09-27 HEBA FASTIGHETS AB: SE0013882875, 2026-03-02 SWEDISH MATCH AB: XS1619638528, 2022-05-30 SWEDISH MATCH AB: XS2306815114, 2026-02-24 SVENSKA CELLULOSA AB SCA: SE0013882560, 2025-09-23 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-03-14Bid date2021-04-14Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS0328561286: 30 mln SEK +/-30 mln SEK SE0012193860: 30 mln SEK +/-30 mln SEK SE0013882875: 30 mln SEK +/-30 mln SEK XS1619638528: 30 mln SEK +/-30 mln SEK XS2306815114: 30 mln SEK +/-30 mln SEK SE0013882560: 30 mln SEK +/-30 mln SEK Highest permi
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER9.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-14CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-10-14 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-04-02 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-04-14Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS9.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-16BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 KINGDOM OF SWEDEN: REGS, XS2226974504, 2030-09-09 Bid date2021-04-16Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1062: 750 mln SEK +/-400 mln SEK 1053: 500 mln SEK +/-250 mln SEK REGS: 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1062: 750 mln SEK per bid 1053: 500 mln SEK per bid REGS: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-20Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-04-09 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation